Business Context and Reporting Period
This Form 8-K Current Report was filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on July 10, 2018, covering events occurring on July 4, 2018. The filing addresses the departure of a key executive and board member, Jona Zumeris, who served as Vice President of Technology and a Director.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and separation terms.
Material Changes
The primary material change is the resignation of Jona Zumeris from all positions, effective July 4, 2018. The resignation was not due to any disagreement regarding the Company's operations, policies, or practices. A Separation and Release Agreement was executed to govern the transition and future compensation.
Guidance, Outlook, and Management Commentary
The filing details a complex compensation structure for the departing executive rather than providing forward-looking business guidance:
- Consulting Payments: An aggregate of NIS 65,000 per month for 12 months, commencing 30 days after the termination date, contingent on meeting technical and administrative milestones.
- Stock Sale Floor: The Company will use best efforts to allow the sale of Dr. Zumeris's securities starting November 4, 2018. If the aggregate value of unsold securities and cash proceeds remains below $950,000 after 14 months (and shares were not sold below $4.45), the Company will make up the difference by extending the consulting term and payments.
- Technology Milestones: Additional payments of up to $100,000 are tied to specific outcomes:
- 10% of payments received from licensing skin rejuvenation technology.
- $100,000 from proceeds if the technology is sold as a standalone product.
- $5 per unit for sales of skin rejuvenation devices, capped at $100,000.
The agreement includes standard releases of claims and restrictive covenants regarding intellectual property, non-disparagement, and non-compete.
Investor Verification Checklist
- Verify the exact terms of the Separation and Release Agreement filed as Exhibit 10.1.
- Confirm the current status of the "technical and administrative milestones" required to trigger the monthly consulting payments.
- Monitor the trading price of NanoVibronix common stock to assess the likelihood of the $950,000 aggregate value floor being triggered.
- Track any future licensing or sales of the skin rejuvenation technology to determine potential additional liability to the former executive.